- Original Article
- The Safety and Immunogenicity of a Trivalent, Live, Attenuated MMR Vaccine, PriorixTM
-
Seung-In Ahn, Min-Kook Chung, Jung-Suk Yoo, Hye-Jeon Chung, Jae-Kyun Hur, Young-Kyu Shin, Jin-Keun Chang, Sung-Ho Cha
-
Clin Exp Pediatr. 2005;48(9):960-968. Published online September 15, 2005
-
|
|
Purpose : This multi-center, open-label, clinical study was designed to evaluate the safety and immunogenicity of a trivalent, live, attenuated measles-mumps-rubella(MMR) vaccine, PriorixTM in Korean children.
Methods : From July 2002 to February 2003, a total of 252 children, aged 12-15 months or 4-6 years, received PriorixTM at four centers : Han-il General Hospital, Kyunghee University Hospital, St. Paul's Hospital at... |
-
-
|
